EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience.

ABSTRACT:

Background

About 15% of non-small cell lung cancers (NSCLCs) harbor epidermal growth factor receptor (EGFR) mutations. Upfront treatment with first and second generation EGFR tyrosine kinase inhibitors (1-2gen TKIs) is superior to chemotherapy. The most frequent resistance mechanism to 1-2gen TKIs is EGFR T790M mutation, which is targeted by osimertinib. T790M mutation can be revealed by liquid biopsy (LB) or by tissue rebiopsy (TB). LB is easily feasible but less sensitive than TB. We focused on repeated LBs and analyzed clinical features associated with EGFR T790M detection.

Methods

This is a retrospective multicenter observational study including EGFR-mutant NSCLC consecutive patients with disease progression (PD) after 1-2gen TKIs and with a f

SUBMITTER: Dal Maso A 

PROVIDER: S-EPMC9562526 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature